8-K filed Jun 8, 2026 at 07:15 ET
Tango Therapeutics reported highly encouraging initial Phase 1/2 data for vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib and zoldonrasib) in MTAP-deleted, RAS-mutant pancreatic cancer. The vopimetostat + daraxonrasib arm showed a 92% objective response rate (ORR) and a 90% six-month progression-free survival (PFS) rate in 12 evaluable second/third-line PDAC patients, with a manageable safety profile. The company plans to rapidly advance this combination into a Phase 3 randomized-controlled trial in front-line pancreatic cancer, subject to regulatory feedback.